hero image

Biogen Idec Names Caroline Dorsa to Board of Directors

January 4, 2010 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ:BIIB) today announced the appointment of Caroline Dorsa, Executive Vice President and Chief Financial Officer of Public Service Enterprise Group (PSEG) and former Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., to its Board of Directors. Ms. Dorsa fills a vacancy on the Board.

“Caroline Dorsa brings exceptional financial expertise, strong strategic thinking and a deep knowledge of the pharmaceutical industry to our Board,” said Biogen Idec Chairman William D. Young. “Her outstanding business experience will enable her to make significant contributions to Biogen Idec as it executes its long-term strategic plan.”

Ms. Dorsa, 50, was named Executive Vice President and Chief Financial Officer of PSEG, a publicly traded diversified energy company with annual revenues of more than $13 billion, in April 2009. Prior to that, she had served as Senior Vice President, Global Human Health, Strategy and Integration at Merck since early 2008. From 1987 to 2006, she served in various financial positions at Merck, including Vice President and Treasurer. In 2007, she was named Senior Vice President and CFO at Avaya, Inc. and then held the same positions at Gilead Sciences, Inc. before rejoining Merck in 2008. Earlier in her career, Ms. Dorsa worked for Mayor Ed Koch of the City of New York promoting economic development in midtown Manhattan. Ms. Dorsa holds a B.A. from Colgate University and an M.B.A. from Columbia Business School.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Contact:

 

Biogen Idec Media:
Amy Reilly, 617-914-6524
Associate Director, Public Affairs
or
Biogen Idec Investor Relations:
Eric Hoffman, 617-679-2812
Director, Investor Relations

thumb
May 16, 2024
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of

thumb
May 14, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the